Small Cap Feast
Small Cap Feast – 22 May 2020
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
The pantry is empty, again!
Synectics 120p £21.3m (SNX.L)
Two new multi-year contracts with existing long-term customers.
Synectics’ Systems division has been awarded a new five-year multi-million dollar support contract by a major casino operator for its flagship resort in Asia, further extending an existing long-term relationship. Secondly, Synectics’ IMS division has been awarded a new three-year framework agreement by Stagecoach, the UK’s largest bus and coach operator. The contract is an extension of Synectics’ 18-year relationship with Stagecoach and covers the delivery of safety critical on-vehicle surveillance systems and maintenance support for their fleet of over 8,000 vehicles.
Coro Energy 0.475p £3.8m (CORO.L)
All necessary Indonesian regulatory approvals for the transfer of title of the 15% direct interest in the Duyung PSC to Coro have now been received. Accordingly, final completion of the acquisition of the PSC Interest by the Company from West Natuna Exploration Ltd has now been achieved. The Company looks forward to the publication of the revised independent reserve audit report from Gaffney Cline & Associates following the successful appraisal drilling campaign in the fourth quarter of 2019, which is expected to be announced later in the month.
Proactis Holdings 37p £35.3m (PHD.L)
The Group has signed new contracts with a total contract value of £11.3m cumulatively in the year to date, which equals the equivalent performance for the whole of the prior financial year.
This improved new business performance has been driven by the Group’s refreshed go-to-market strategy and, in tandem with improved retention performance, annual recurring revenue from the Group’s buyer subscription business has returned to organic growth for the year to date.
Eco Animal Health 208p £141m (EAH.L)
Subsidiary ECO Animal Health Limited (ECO) has received a positive opinion from the European Medicines Agency (EMA) for the use of Aivlosin® 625 mg/g Water Soluble Granules (WSG) for the treatment and metaphylaxis (disease control) of Mycoplasma hyopneumoniae in pigs. Mycoplasma hyopneumoniae is the most common primary pathogen in pig respiratory disease and is a key instigator of secondary bacterial and viral pathogens.
Aivlosin®, ECO’s patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs. The European Commission is expected to issue a marketing authorisation within two months of the publication of a positive opinion.
Codemasters 312p £473 (CDM.L)
Update regarding the launch of Fast & Furious Crossroads (the “F&F Game”), the licensed IP game that is being developed by recently acquired studio, Slightly Mad Studios, originally scheduled for release in May 2020.
Following close consultation with our partners at BANDAI NAMCO Entertainment Europe and Universal Games and Digital Platforms, the Company can confirm that an agreement has been reached to launch the F&F Game in the second quarter of the Company’s current financial year, being the three months to 30 September 2020.
Accordingly, the Board of Codemasters confirms that this later launch date is not expected to have a material impact on its financial expectations for FY21.
genedrive 178.5p £62.2m (GDR.L)
The near patient molecular diagnostics company, announces that the Genedrive® 96 SARS-CoV-2 Kit is now CE-IVD marked and is available for commercial sale across the European Union, including the UK, whilst also accelerating market access to countries that accept the CE-IVD mark.
The Genedrive® 96 SARS-CoV-2 Kit is a novel Polymerase Chain Reaction (PCR) assay designed to detect active infection in COVID-19 patients. genedrive’s PCR bead format eliminates the need for the time consuming and error-prone reagent preparation required in all other open-platform test kits. The proprietary format streamlines laboratory workflow, allowing more tests to be performed in a day. Patient samples are simply mixed with the PCR beads, and are then analysed on a variety of existing third-party real time PCR platforms. During CE-IVD evaluations on 180 randomised specimens, the Genedrive® 96 SARS-CoV-2 Kit achieved 100% sensitivity and 98.2% specificity, placing it in a top tier performance table for COVID-19 PCR tests.
Tissue Regenix 0.475p £5.6m (TRX.L)
Confirmation of successful fundraising of £ 14.6 million at 0.25p. Following significant excess demand, the Company has increased the overall size of the Fundraise. “We continue to experience strong demand for our products. This injection of additional capital will allow for the commencement of the planned manufacturing capacity expansion in the US enabling us to increase the output of our San Antonio facility, unlock additional revenues and realise new partnership opportunities we foresee potentially emerging.”
Time Out Group 40p £59m (TMO.L)
The Company today announces it is proposing to raise up to £49 million, before expenses, by way of a Placing to raise gross proceeds of up to approximately £45 million and an Open Offer to raise gross proceeds of up to approximately £4 million, in each case at an issue price of 35 pence . The Company also announces that it has today entered into the amendment and restatement of the terms of the Group’s €22.6 million (approximately £20.2 million) outstanding debt facilities from Incus Capital Advisers, S.A.
The net proceeds of the Equity Fundraising will be used primarily to support general working capital requirements and strengthen the Company’s balance sheet in the wake of the impact of COVID-19, to part fund continuing Time Out Markets capital expenditure, to continue developing the new London Waterloo and Porto Markets and to (conditionally) redeem the OCI Loan Notes in full.
Tekcapital 14.5p £12.7m (TEK.L)
Portfolio Company Guident has won the Florida Atlantic University (FAU) Tech Runway® Annual tech Launch competition as one of the most promising startups in South Florida . A panel of judges, including successful entrepreneurs, technology investors, entrepreneurship professors, economic development professionals, philanthropists, and commercial bankers selected Guident as the winner of the competition. The judges were convinced that the company seeking to create a Remote Monitoring and Control Center, (“RMCC”) in Florida for autonomous vehicles applying artificial intelligence, and their first use-case for ‘zero-touch’ ground-based delivery of groceries and medicines would be the right choice to create significant value in South Florida and Nationwide.
ITM Power 224p £1.1bn (ITM.L)
The energy storage and clean fuel company, announced the formation of the H2OzBus Project and the signing of a memorandum of understanding with strategic partners. The Consortium comprises Transit Systems, part of the SeaLink Travel Group, Ballard Power Systems, BOC Limited, Palisade Investment Partners and ITM Power. The Consortium partners have signed a memorandum of understanding as a further step in evaluating and demonstrating the concept of hydrogen fuel cell electric buses for use in public bus transport in Australia.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.